(Q37856552)

24 August 2017

1 reference

title

The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children (English)

1 reference

24 August 2017

1 reference

1 reference

1 reference

P R Donald

1

1 reference

24 August 2017

J S Maritz

series ordinal

2

1 reference

24 August 2017

A H Diacon

series ordinal

3

1 reference

24 August 2017

publication date

22 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

91

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

196-207

1 reference

Antituberculous drug doses in children

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Human Hepatic CYP2E1 Expression during Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Developmental expression of human hepatic CYP2C9 and CYP2C19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacokinetics of rifapentine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Clinical evaluation of chemotherapeutic drugs in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Effect of meals on rifampicin absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Effect of food on bioavailability of rifampicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Binding of rifampicin by human plasma proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Ethambutol and rifampicin serum levels in children: Second report on the combined administration of ethambutol and rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacodynamic Interference between Rifampicin and Isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacokinetics of rifampin in children. II. Oral bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Rifampicin kinetics in undernutrition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Half-Life of Rifampicin after Repeated Administration of Different Doses in Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Serum rifampicin concentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Salivary levels of isoniazid and rifampicin in tuberculous patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Drug Interaction between Rifampicin and Cotrimoxazole in Patients with Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

DEVELOPMENTAL PHARMACOLOGY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Paediatric drug dosing. Bodyweight versus surface area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

A trial involving HIV-tuberculosis in India: the minute particulars

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.02.004

10.1016/J.TUBE.2011.02.004

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference